Malignant Melanoma of the Gastrointestinal Tract: Symptoms, Diagnosis, and Current Treatment Options.
Loading...
Embargo End Date
ICR Authors
Authors
Kohoutova, D
Worku, D
Aziz, H
Teare, J
Weir, J
Larkin, J
Worku, D
Aziz, H
Teare, J
Weir, J
Larkin, J
Document Type
Journal Article
Date
2021-02-05
Date Accepted
2021-01-29
Date Available
2022-08-26T09:56:40Z
Abstract
Malignant melanoma (MM) has become the fifth most frequent cancer in the UK. It is the most common carcinoma to metastasize to the gastrointestinal (GI) tract. MM particularly has an affinity to spread to the small bowel, which is followed by the involvement of the stomach and large intestine. Excellent endoscopic options including video capsule endoscopy and enteroscopy are available for a precise diagnosis of GI involvement by a metastatic MM. The complete surgical resection of GI metastatic MM in carefully selected patients not only provides symptom control, but has also been associated with an increase in overall survival. The approval of BRAF-targeted therapies and immune checkpoint inhibitors has transformed therapeutic approaches for patients with metastatic MM over the past decade. Currently, the overall survival of patients with advanced metastatic MM who have been treated with a combination of immunotherapeutic agents reaches 52% at five years. The role of surgery for patients with the metastatic involvement of the GI tract with MM is evolving in the era of effective systemic treatments.
Citation
Cells, 2021, 10 (2), pp. 327 -
Source Title
Cells
Publisher
MDPI
ISSN
2073-4409
eISSN
2073-4409
2073-4409
2073-4409